Penny Stocks in Focus - Generex Biotechnology Corporation (OTCMKTS:GNBT ... SBWire (press release) Las Vegas, NV -- (SBWIRE) -- 08/31/2013 -- Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental ... Trend Analysis Report - Perrigo Company (NYSE:PRGO), Generex ...Techsonian all 7 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFg-mDWWhl5WyjGpOL3jBcvGk_HCA&url=http://www.sbwire.com/press-releases/penny-stocks-in-focus-generex-biotechnology-corporation-otcmktsgnbt-titan-pharmaceuticals-inc-otcbbttnp-geltech-solutions-inc-otcmktsgltc-international-stem-cell-corp-otcmktsisco-319238.htm

NC Biotechnology Center awards $3.5M in grants, loans WRAL Tech Wire Research Triangle Park, N.C. — Life science start-up companies, event sponsors, researchers and educators received $3.58 million in loans and grants from the North Carolina Biotechnology Center during the final quarter of the fiscal year ended June 30 ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFqvsHH_CGAaI3ixn9d5XVQ4r8TYg&url=http://wraltechwire.com/nc-biotechnology-center-awards-3-5m-in-grants-loans-/12809124/

Myriad decision aftershocks ripple through biotech Nature.com “That's one reading of the case,” says Hans Sauer of the Biotechnology Industry Organization (BIO) in Washington, DC. But a broad interpretation could extend the Court's logic to other molecules, he says. Indeed, its reasoning could translate pretty ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNE8XUji99_Ua3N841TVcHCXLuSwuA&url=http://www.nature.com/nbt/journal/v31/n8/full/nbt0813-663.html

Data on Biotechnology Reported by Researchers at King's College HispanicBusiness.com By a News Reporter-Staff News Editor at Veterinary Week -- A new study on Biotechnology is now available. According to news reporting out of London, United Kingdom , by VerticalNews editors, research stated, "The interdisciplinary EC consortium (the ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH3rvstf0rKd8jV4yWqapeImbOm9A&url=http://www.hispanicbusiness.com/2013/8/23/data_on_biotechnology_reported_by_researchers.htm

Hoosier Ag Today

Still Time to Register for International Biotechnology Symposium Aug. 26 Hoosier Ag Today ibs_logo Fortunately, U.S. and international biotechnology companies will have dozens of new transgenic events that increase crop yields and quality ready for registration by 2015. Unfortunately, the world is lacking a synchronized, science-based ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFunn7acgop8h56umJtkZgVHMJTyA&url=http://www.hoosieragtoday.com/still-time-to-register-for-international-biotechnology-symposium-aug-26/

Pro and anti-GM crop groups slug out the controversial issue in power corridors Times of India ... storage denying farmers and the nation the benefits of modern science and technology. Let science innovate. Let Indian scientists research freely. And let farmers choose," said Desh Pal Verma of the department of molecular genetics, Ohio State ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNF1ZnkfUeBbqdzkkECxcpGrr07jxA&url=http://timesofindia.indiatimes.com/india/Pro-and-anti-GM-crop-groups-slug-out-the-controversial-issue-in-power-corridors/articleshow/22008822.cms

James Gollub: 'economic therapist' Gollub Associates photo

“A leading expert in innovation
bridge building....
“Global experience assisting
universities, institutes, government agencies and public-private
partnerships link innovation sources to innovation
seekers.
“Committed to the goal of increasing flow of needed
solutions, optimizing financial returns and sustainable economic
impacts from innovation.”

“James Gollub Associates
(JGA) LLC was launched to build on 36 years of Gollub’s
professional research and consulting experience. That experience
began with 16 years at SRI International, three years at
DRI/McGraw-Hill, five years at IDeA, nine years at ICF International
and three years with E-Cubed Ventures LLC. During that
time Gollub has worked globally to deliver
economic strategies for over 30 national, state and metropolitan
regions, develop strategies to accelerate growth of new industries
(clusters), plan public and private R&D institutes and advise on
over 15 science and technology parks.”

The need for a financial transition plan for CIRM was publicly identified as long ago as 2009 by the Little Hoover Commission in its lengthy study and has been reiterated periodically by other bodies since then. Under the terms of Prop. 71, which created the agency, CIRM has only  a 10-year authority to issue state bonds, the borrowed funds that have sustained the research effort. Legal maneuvering blocked the issuance of bonds until 2007.

The California Stem Cell Report asked
the stem cell agency on May 31 for a copy of Gollub's response to the
RFP. Yesterday we asked for a copy of the contract with Gollub. Those
documents will be published when they are received.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/tncFJBJJM5I/california-stem-cell-agencys-150000.html

“This is aimed at trying to jump
start the creation of the partnerships that are required to satisfy
the commercial validation requirements of the Strategic Partnership
Funding Initiative so that timelines are better synced-up as between
our review and approval cycles for the Strategic Partnership RFAs and
the lengthy time required for investors to conduct due diligence and
negotiate an agreement with prospective applicants to Strategic
Partnership RFAs.  CIRM's independent review and approval
remains the same and is wholly independent. While there may be input
given to a particular RFA it only at the high level concept stage and
of course CIRM has no obligation to agree. In the context of the
Strategic Partnership awards, CIRM wants to fund innovative high
quality science that has attracted additional  investors.
 Investors will help leverage CIRM fund and will be an important
source of future funding to further the project.”  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/ZtmnBmRh5K0/new-ties-to-big-pharma-and-venture.html

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/5UwFuEaKpJM/a-2-million-bill-outside-contracting-by.html

Analysis of CIRM funding by Pat Olson, executive director of CIRM scientific activities July 2013

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/gzZM85Gu0ME/california-stem-cell-agency-spending.html

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/MsXTjRpEcFY/flim-flam-stem-cell-artists-targeted-by.html

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/rt53_NIUkj8/california-stem-cell-researchers-to.html

Sizzling Penny Stocks - Generex Biotechnology Corporation (OTCMKTS:GNBT ... SBWire (press release) Generex Biotechnology Corporation (www.generex.com) (GNBT) announced publication of follow up studies from a Phase I clinical trial of its immunotherapeutic agent AE37 in patients with prostate cancer. The Phase I study demonstrated that the compound ... Stocks on the Move-Generex Biotechnology Corporation (OTCMKTS: GNBT ...Techsonian all 7 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH9gKYCEUsygWZ9iWFzJadwaeXuOg&url=http://www.sbwire.com/press-releases/sizzling-penny-stocks-generex-biotechnology-corporation-otcmktsgnbt-titan-pharmaceuticals-inc-otcbbttnp-patient-safety-technologies-inc-otcmktspstx-ecosphere-technologies-inc-otcbbesph-313509.htm

The bad news: "Stem cells by themselves do not work."

The good news: "Stem cells by themselves do not work."

Take it from the doctor who has treated 5,000 patients with stem cell therapy, a doctor who is himself a cancer survivor. Thirteen years ago, Dr. Sam Bernal - oncologist, chemist, molecular biologist, lawyer, professor and lecturer, among other things - was a cancer patient who thought he was at death's door. Using stem cells sourced from his bone marrow and peripheral blood, he overcame the disease and has since become an advocate of living fit, living well in order to look good.

Dr. Bernal, who divides his time between Los Angeles, Prague, Makati, and Germany, was a pioneer in stem cell research in the Philippines early on in his career, for which he was cited when he received the Presidential Award for Outstanding Filipinos Overseas from President Benigno S, Aquino III in 2012.

At a recent meeting with journalists, Dr. Bernal hurled the challenge: "What do you need stem cell therapy for if you eat well, sleep soundly, exercise regularly, don't smoke, have a positive attitude, and know how to live in the moment as you gaze at a painting and get a thrill out of small things like that?"

Not only is the doctor a passionate advocate of living the good life, the simple life, and, yes, Argentine tango - "It's better than boring exercises at the gym!" - he believes in healthy eating. "I brought a group of European friends to Manila and they were flabbergasted at our vegetable dishes - laing, gising-gising, buko juice - our simplest food was gourmet cuisine to them!"

No, he's not a vegetarian, but a "flexitarian."

But if stem cells - the body's own master and repair cells - aren't the key to staying young, what is? The holistic approach works best, according to the doctor, stating that the procedure should be recommended by doctors "on a case by case basis." In effect, the doctor prescribes "customizing your stem cell therapy."

In his book, molecular biology provides the battleground from which to attack the afflictions of aging that signal a desire or need to repair or replace one's stem cells. Speaking of books, Dr. Bernal continues to teach at Harvard, Ateneo, UST, and Medical City as a component of his mission to spread the benefits of technology transfer, which is the vision of his company, GlobeTek Science Foundation (based in Makati).

Excerpt from:
‘Customize’ your stem cell therapy

Stem cell therapy treats animal ailments, vets see improvement
Stem cell therapy is typically tied to controversy but now, some Southern Arizona veterinarians are turning to a different form of the cutting edge treatment...

By: kgun9

See the original post here:
Stem cell therapy treats animal ailments, vets see improvement - Video

Bearded Collie OA BEFORE Stem Cell Therapy

By: MediVet Arizona

Original post:
Bearded Collie OA BEFORE Stem Cell Therapy - Video

2 months after stem cell therapy
Eveybody agrees that the therapy works. There is very big improvment the way Toby walks now.

By: Jacek Kozlowski

More here:
2 months after stem cell therapy - Video

By: Jet Villa, InterAksyon.com August 20, 2013 3:45 PM

InterAksyon.com The online news portal of TV5

MANILA, Philippines Reminder for those who wish to have their stem cell therapy practice and products accredited: You have until August 31 to register, the Department of Health said Tuesday.

Citing Administrative Order 2013-0012 issued March 18 this year, Health Secretary Enrique Ona said that while the Department of Health (DOH) supports scientific advancement in the field of cellular medicine, its priority is to protect the public from harm rather than give a blanket endorsement of its use or potential benefits.

Those who need to seek accreditation include: health care facilities doing stem cell therapy (with the DOH) as well as companies that import, market, and produce stem cell products (with the Food and Drug Administration, which is under DOH).

Ona said the DOH seeks to regulate stem cell therapy both as a recognized treatment modality and for research purposes.

"This is to allay fears that unscrupulous individuals or groups will engage in unethical practices and subject naive patients to undue harm and unproven medical claims," he added.

Among the DOH guidelines are:

Ona conceded that there are only a limited number of medical conditions in which stem cell therapy may be indicated.

Others are claims that should be taken with a grain of salt, he said.

The rest is here:
REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 - DOH

By Philip C. Tubeza Philippine Daily Inquirer

MANILA, PhilippinesSaying that doctors were exacting exorbitant fees for what is still experimental medicine, the Philippine College of Physicians (PCP) launched Tuesday an online petition urging the Department of Health (DOH) to put a stop to experimental stem cell therapies in the country.

Human stem cell therapy for unproven indications is proliferating in the Philippines and posing serious safety issues to unknowing Filipinos The Philippine College of Physicians is alarmed by the false claims, misinformation and exorbitant fees for such stem cell treatments, read the petition on http://www.change.org.

The PCP urged the DOH to issue a cease and desist order to all doctors performing such therapies as the Philippine Health Insurance Corp. (PhilHealth) clarified that stem cell therapy was not covered by the governments universal healthcare program.

Cease and desist

We, the undersigned, call on the (DOH) to issue a cease and desist order to all doctors, clinics and hospitals that [offer] human stem cell therapy for unproven indications until scientific evidence to support claims of efficacy and safety are approved by the Food and Drug Administration, it said.

The PCP, the umbrella organization of Internal Medicine specialists in the country, said that transplanting human blood-forming stem cells to treat cancerous and noncancerous diseases of the blood was the most widely accepted clinical application of stem cell therapy.

The effectiveness and safety of human stem cell therapy has yet to be proven for heart, neurologic, skin, rheumatologic and gastrointestinal diseases, diabetes, hypertension, autism, cancer, aging and aesthetics, HIV/AIDS and other conditions, the group said.

Lack of evidence

Despite the lack of solid scientific evidence to support the [application] of human stem cell therapy for these conditions, reports of its use precisely for these conditions being received and exorbitant fees being paid by prominent personalities abound in media, the PCP said.

The rest is here:
Docs seek stop to expensive, experimental stem cell therapy

CHEYENNE, WY- (ACCESSWIRE - August 20,2013) - Therapy Cells Inc (OTC Pink: TCEL) announces that on 13 February 2013, US patent US 11/702,895 was awarded to renowned scientist Dr Patrick Casey and Transplantation Ltd, for his transformational cell therapy, exclusively licensed to Therapy Cells Inc for use in human applications.

This revolutionary science dispenses with the traditional notion that cells cannot divide once they are fully mature. Dr Casey has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory. These new cells can then be used for transportation back to damaged tissue in the body, to enact tissue and organ healing.

The research team headed by Dr Casey has to date treated more than 80 horses including thoroughbreds, standardbreds, polo ponies and horses at the highest level of equestrian competition.

"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order have human applications in human tendons," Dr Casey says. "An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in humans, will likely increase this factor by at least 10 times." The horse is an FDA approved model species for athletic injuries.

Dr Casey is a Veterinary graduate from Massey University (BVSc, 1988), and graduate from the University of California in 1992 with a Doctor of Philosophy (PhD, Comparative Pathology). During his time in the United States he also completed an Equine Surgical Internship at Hagyard-Davidson and McGee, Lexington, Kentucky, followed by a three year residency programme in Equine Reproduction, with a minor in Equine Medicine at UC Davis. In 1992, 1993, and 1994 he received a post-doctoral fellowship from the Equine Research Laboratory at the University of California, which allowed him to set up with the late, world renowned, Professor Liggins at the University of Auckland, New Zealand.

Since 2011, Dr Casey has been chief scientific consultant to a public company in the USA - Therapy Cells Inc (TCEL on the OTC Market).

This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and regeneration of that tissue, effectively by-passing the need for Stem Cell treatment.

"The financial and curative potential of this biotechnology platform is immediately obvious," states Dr Casey. "When we talk about regenerative procedures, the ability to rejuvenate tissues and organs with cultivated natural cell therapy, it's easy to understand how enormous the opportunity and the impact will be. The awarding of this US Patent for our transformational science is a significant milestone in the steps we have been taking to get our therapies to market."

Contact:

Contact: Patrick Casey

See the article here:
Therapy Cells, Inc Receives USA Patent Granted for Revolutionary Cell Therapy